Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

The International Serious Adverse Events Consortium

Nature Reviews Drug Discovery volume 13, pages 795–796 (2014)Cite this article

Subjects

The International Serious Adverse Events Consortium is generating novel insights into the genetics and biology of drug-induced serious adverse events, and thereby improving pharmaceutical product development and decision-making.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Holden, A. L. The SNP consortium: summary of a private consortium effort to develop an applied map of the human genome. Biotechniques 32, S22–S24 (2002).

    Article  Google Scholar 

  2. Contreras, J. L., Floratos, A. & Holden, A.L. The International Serious Adverse Events Consortium's data sharing model. Nature Biotech. 31, 17–19 (2012).

    Article  Google Scholar 

  3. Contreras, J. L. Bermuda's legacy: policy, patents, and the design of the genome commons. Minn. J. Law Sci. Technol. 12, 61–125 (2011).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. iSAEC, 8770 West Bryn Mawr Avenue, Suite 1300, Chicago, 60631, Illinois, USA

    Arthur L. Holden

  2. and Department of Human Genetics, iSAEC and at the S.J. Quinney College of Law, University of Utah, Salt Lake City, 84112, Utah, USA

    Jorge L. Contreras

  3. iSAEC Scientific Management Committee and at Pfizer, New London, 06320, Connecticut, USA

    Sally John

  4. iSAEC Scientific Management Committee and at GlaxoSmithKline, Research Triangle Park, 27709–3398, North Carolina, USA

    Matthew R. Nelson

Authors
  1. Arthur L. Holden
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jorge L. Contreras
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sally John
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Matthew R. Nelson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Arthur L. Holden.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Supplementary information S1 (table)

Summary of case enrolment by iSAEC and status of phase 2 pipeline (PDF 761 kb)

Supplementary information S2 (Box)

Publications from the International Serious Adverse Events Consortium to date (as of September 2014) (PDF 110 kb)

Related links

Related links

FURTHER INFORMATION

iSAEC Data Access Site

iSAEC Public Data Access Policy

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Holden, A., Contreras, J., John, S. et al. The International Serious Adverse Events Consortium. Nat Rev Drug Discov 13, 795–796 (2014). https://doi.org/10.1038/nrd4441

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd4441

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research